T100 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
299嚢胞性線維症3

299. 嚢胞性線維症


臨床試験数 : 1,695 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2007-000959-33-DE
(EUCTR)
16/08/200704/04/2007Randomized, open labelled, cross over deposition study of Tobramycin 100 PARI nebulized with eFlow® versus TOBI® nebulized with PARI LC PLUS® in subjects with CFRandomized, open labelled, cross over deposition study of Tobramycin 100 PARI nebulized with eFlow® versus TOBI® nebulized with PARI LC PLUS® in subjects with CF Cystic Fibrosis with Pseudomonas aeruginosa infectionProduct Name: Tobramycin 100 PARI
Product Code: T100 PARI
INN or Proposed INN: Tobramycin
Trade Name: TOBI®
INN or Proposed INN: Tobramycin
PARI GmbHNULLNot RecruitingFemale: yes
Male: yes
25Germany
2EUCTR2005-004103-10-DE
(EUCTR)
03/05/200630/01/2006Randomized, open labeled, multi center, active controlled, parallel 28 days safety and bioavailability study of Tobramycin 100 PARI nebulized with eFlow® versus TOBI® nebulized with PARI LC PLUS in cystic fibrosis patients with Pseudomonas Aeruginosa infectionsRandomized, open labeled, multi center, active controlled, parallel 28 days safety and bioavailability study of Tobramycin 100 PARI nebulized with eFlow® versus TOBI® nebulized with PARI LC PLUS in cystic fibrosis patients with Pseudomonas Aeruginosa infections Cystic Fibrosis with Pseudomoas aeuriginosa infection
MedDRA version: 8.1;Level: LLT;Classification code 10011763;Term: Cystic fibrosis lung
Product Name: Tobramycin 100 PARI
Product Code: T100 PARI
INN or Proposed INN: Tobramycin
Trade Name: Tobi
Product Name: TOBI®
INN or Proposed INN: Tobramycin
PARI Pharma GmbHNULLNot RecruitingFemale: yes
Male: yes
60Germany
3EUCTR2010-023235-41-PL
(EUCTR)
28/01/2011A comparative, randomised, two period, multi-center, cross-over 14 weeksbioequivalence study of Tobramycin PARI (T100) versus TOBI® (Novartis) incystic fibrosis patients with bronchopulmonary chronic Pseudomonasaeruginosa infection - T-100 BEA comparative, randomised, two period, multi-center, cross-over 14 weeksbioequivalence study of Tobramycin PARI (T100) versus TOBI® (Novartis) incystic fibrosis patients with bronchopulmonary chronic Pseudomonasaeruginosa infection - T-100 BE Cystic fibrosis with bronchopulmonary chronic Pseudomonas aeruginosa infection
MedDRA version: 12.1;Level: LLT;Classification code 10011763;Term: Cystic fibrosis lung
Product Name: Tobramycin
Product Code: T100
INN or Proposed INN: Tobramycin
Other descriptive name: Tobramycinum
Trade Name: TOBI®
INN or Proposed INN: TOBRAMYCIN
PARI Pharma GmbHNULLNot RecruitingFemale: yes
Male: yes
60Phase 1Poland